According to a meta-analysis done in 2018 of three randomized, double-blinded trials (n = 304): phase I and II, ACT-34 extension, and phase III RENEW, CD34+ therapy improved TET, AF, and MACE in patients with refractory angina. This evidence concerns the gene CD34 and atrial fibrillation.